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The efficacy and tolerability of vigabatrin as add-on therapy was assessed in patients with uncontrolled partial 
seizures. Ninety-seven patients entered this seven-centre, double-blind, placebo-crossover study. Vigabatrin (2 g or 
3 g) or placebo was administered daily. 
Vigabatrin was well-tolerated and did not cause clinically significant adverse drug effects when added to 
established anticonvulsant therapy. No significant differences were observed between dose groups for the overall 
incidence of adverse events, although drowsiness and visual disturbances (diplopia, ataxia, visual abnormalities) 
showed a dose-related increase with vigabatrin treatment. The results of this study indicate that vigabatrin, given in 
a daily dose of either 2 g or 3 g is significantly more effective than placebo in reducing seizure frequency among 
patients with partial seizures. 
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INTRODUCTION 
Vigabatrin, a structural analogue of gamma- 
aminobutyric acid (GABA), is an irreversible 
inhibitor of GABA-transaminase, the enzyme 
that catabolizes GABA to succinic 
semialdehyde’. The resultant increase in brain 
GABA levels within the central nervous system 
has been established in animal models and in 
manz4. GABA is the major inhibitory neuro- 
transmitter in the mammalian brain. A reduction 
in GABA concentrations has been associated 
with the disruption of normal neurological 
control and the abnormal, hypersynchronous 
activation of large groupings of contiguous 
neurones, predisposing to seizure activity’. 
To date, the drug therapy of patients with 
epilepsy has been associated with a decrease in 
seizure frequency in approximately 80% of those 
treated5. The remaining 20% are refractory to 
treatment with routine antiepileptic drugs 
(AEDs) and require intensive therapy, often with 
more than one agent, to achieve optimal seizure 
control. The results of double-blind, placebo- 
controlled studies indicate that the addition of 
vigabatrin to standard antiepilepsy therapy can 
significantly decrease seizure frequency and seve- 
rity in drug-refractory patients experiencing 
complex partial seizureP. 
In these studies of vigabatrin, approximately 
one half of the patients receiving vigabatrin 
therapy experienced a 50% or greater reduction 
in seizure frequency compared with those receiv- 
ing placebo treatment. Vigabatrin has been found 
to be well-tolerated, with adverse events occur- 
ring most commonly during the early phase of 
therapy and decreasing in incidence with con- 
tinued therapy”. 
The results of a dose-ranging study’, together 
with supportive evidence derived from a meta- 
analysis of published European placebo- 
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controlled studies of vigabat&, indicate that 
doses of 1.5 g/day or greater are effective as 
add-on therapy for uncontrolled complex partial 
seizures. The majority of European studies have 
evaluated a 3 g daily dose of vigabatrin. Patients 
treated with 1.5 g/day have shown a signficant 
reduction of seizure frequency compared with 
pretreatment rates; however, this response was 
smaller than that observed among patients 
treated with higher doses”‘. 
The study reported here examined the efficacy 
and tolerability of two daily doses of vigabatrin 
(2g and 3 g) to define more fully the optimal 
effective dose in patients with complex partial 
seizures refractory to therapy with established 
AEDs. Vigabatrin therapy was added to currently 
prescribed AED therapy and compared with 
placebo in patients with resistant complex partial 
seizures. 
METHODS 
Patients of either sex, aged between 16 and 65 
years, were included in the study. Eligibility 
required that all patients had at least nine 
documented complex partial seizures during the 
previous two months, despite a stable regimen of 
treatment (AEDs confirmed by steady-state 
plasma drug levels) with currently available 
AEDs, recorded in a patient diary. Seizure 
activity must have severely affected the patient’s 
way of life; the patients must have been treated 
with stable regimens of up to three other AEDs 
during the two months before the study. 
Patients were excluded from the study if they 
had a treatable seizure aetiology (e.g. metabolic 
or neoplastic cause), if they had experienced 
more than one episode of status epilepticus 
during the previous six months, had a history of 
alcoholism or drug addiction, were unable to 
comply with completing the seizure frequency 
calendars, or if they had evidence of other 
systemic disease that would subject them to 
undue risk or would compromise the objective of 
the study. Women of childbearing potential were 
excluded from the study unless an acceptable 
method of contraception was used. All patients 
gave written, informed consent, and institutional 
Ethical Review Committee approval was ob- 
tained at each study site. 
All patients were maintained on their estab- 
lished AED treatments throughout the study. 
Other medications affecting the central nervous 
system were continued for as long as possible, and 
all concomitant medications were recorded at 
each clinic visit. No other investigational drugs 
were taken during the study. 
Vigabatrin was supplied as 0.5 g tablets. Each 
dose of active vigabatrin or matching inactive 
placebo was packed in a foil sachet containing 
three tablets which comprised drug and/or 
placebo (i.e. each sachet contained 0, 2 or 3 
placebo tablets and 0, 2 or 3 vigabatrin tablets. 
All medications were administered under double- 
blind conditions according to a computer- 
generated randomization schedule. 
This crossover study was conducted in five 
phases (Fig. 1). During Phase I, an initial 
screening was completed for each patient. This 
required baseline examinations including medical 
history and examination, seizure history, compl- 
ete physical and neurological examination, full 
laboratory test screen, determination of plasma 
levels of current AEDs medication, and baseline 
neuropsychological testing (not presented in this 
report). Patients who met the entry criteria at the 
end of this eight-week observation period con- 
tinued into Phase II. During Phase II, patients 
were randomized to reveive vigabatrin 2 g/day, 
vigabatrin 3 g/day, or placebo. Patients were 
evaluated after four and eight weeks of treat- 
ment, at which time the patient’s seizure diary 
was reviewed and concomitant medication and 
adverse events were recorded. Patients were 
asked to rate any changes in the duration and 
severity of their seizure activity compared with 
the prior washout period. 
Physical and neurological status was assessed at 
the week 4 and week 8 visits. At the end of week 
8, the investigator completed a global evaluation, 
performed a complete laboratory test screen, and 
determined plasma levels of concomitant AEDs. 
Upon completion of this phase, patients entered 
Phase III, during which those patients ran- 
domized to receive vigabatrin had their dose 
reduced, under double-blind conditions, by 
1 g/week, over a four-week period. Placebo- 
treated patients continued to receive placebo 
during this phase. Comprehensive physical, 
neurological, and laboratory testing was con- 
ducted at the end of the four-week period (Phase 
III). All patients were then crossed over so that 
patients who had previously received vigabatrin 
now received the placebo for eight weeks (Phase 
IV), and vice versa according to the randomiza- 
tion schedule. In Phase IV, the frequency of 
patient visits and assessments of patient status 
followed the Phase II schedule. 
Upon completion of this phase, patients en- 
tered a final four-week dose reduction period 
(Phase V), which was similar in design to Phase 
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Fig. 
VGB 3 g/day VGB 3 g/day 
Washout 
4 weeks 
Run-in 
8 weeks Treatment 8 weeks Treatment 8 weeks 
Washout 
4 weeks 
VGB 2 g/day VGB 2 g/day 
Washout 
4 weeks 
Placebo 2 g/day Placebo 2 g/day 
1: Study design for placebo-controlled crossover study of vigabatrin 2 g or 3 g vs. placebo. VBG, Vigabatrin. 
III. Following completion -of Phase V, the 
patient’s response to vigabatrin was assessed and 
appropriate patients were enrolled in a long-term 
extension of vigabatrin treatment. Patients were 
offered continued vigabatrin treatment under a 
different trial protocol, under open conditions, if 
they had experienced more than a 50% reduction 
in seizure rate compared with placebo during 
vigabatrin therapy. Patients with a reduction in 
seizure rate of less than 50%, but whose 
improvement in quality of life was judged by the 
investigator to warrant continued vigabatrin 
therapy, were also offered continued treatment. 
Adverse events were recorded at each clinic 
visit, and the relationship to therapy was assessed 
and coded using World Health Organization- 
preferred terms. Events occurring during the 
dose-reduction phases were assumed to be 
related to the previous treatment. 
The primary efficacy parameter was total 
seizure rate (defined as the monthly seizure rate 
for all seizure types, calculated for each of the 
four-week study periods). Baseline seizure rates 
were analyzed by the Kruskal-Wallis test. The 
data for seizure ratq were assumed to follow 
log-normal distribution; however, because a 
number of patients became seizure-free (a rate of 
0), a log-transformation of rate was not possible, 
and so a square root transformation was con- 
ducted. Statistical analyses were performed using 
analysis of variance accounting for variation due 
to patient, dose group, treatment and treatment 
period. Means for the square root transformed 
data and for the back-transformed (squared) data 
are presented in this report. The carry-over 
effect of vigabatrin into the washout phase was 
assessed using square root transformed seizure 
rates for the run-in and washout periods. The 
number of seizure-free days and longest seizure- 
free interval between treatments were analysed 
by the sign-rank test. 
Global evaluations of well-being were made by 
both the investigator and the patient and graded 
as ‘very good effect’, ‘good effect’, ‘moderate 
effect’, ‘mild effect’, ‘no effect’ and ‘worse’ and 
were analysed by the Cochran-Mantel-Haenszel 
test. 
The incidence of adverse events was compared 
using the Chi-square statistic. Changes in labora- 
tory data from pre-treatment baseline were 
assessed using the sign-rank matched pair test. 
RESULTS 
Patient demographics 
A total of 97 patients (45 men and 52 women) 
ranging in age from 17 to 64 years entered the 
study. All patients were Caucasian. Of these, 17 
patients were excluded from the analysis of 
efficacy; two patients withdrew because of ad- 
verse events, six patients withdrew because of 
non-compliance with study medication, four 
withdrew at their own request, and five withdrew 
for other reasons unrelated to therapy such as 
incomplete visits, inability to keep a seizure 
record, adverse event on placebo and insufficient 
seizure history for inclusion. Therefore, 80 
patients were included in the analysis of drug 
efficacy. Eight of these patients were strictly 
defined as protocol violators but the reasons for 
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the data exclusion were not likely to have affected 
the clinical evaluation of the drug. A subanalysis 
of the 72 patients who precisely met all protocal 
requirements was conducted. No differences were 
observed for the results of the 72 patients 
compared with those of the 80 patients included 
in the overall efficacy analysis, and the data from 
the 80-patient cohort are presented here. 
Seizure-free periods 
The 80 patients (41 men and 39 women) 
included in the analysis of efficacy ranged in age 
from 17 to 64 years (mean: 33.2 years). Twenty 
patients received vigabatrin 2 g/placebo, 22 re- 
ceived placebo/vigabatrin 2 g, 20 received viga- 
batrin 3 g/placebo, and 18 received 
placebo/vigabatrin 3 g. No significant differences 
were observed between treatment groups for any 
baseline demographic or clinical characteristics. 
Total seizure rate 
The mean monthly seizure rate decreased during 
vigabatrin therapy (Table 1). A 34% reduction in 
the total mean back-transformed seizure rate was 
observed during vigabatrin therapy (21.06) com- 
pared with placebo treatment (13.83). Similarly, a 
39% reduction was observed based on a total 
median monthly seizure frequency. Forty-two per 
cent (34/80) of patients had a 50% or greater 
reduction of seizure frequency during active 
treatment, compared with palcebo. 
During the study, 18 patients reported seizure- 
free periods of at least four weeks’ duration; three 
of these patients were excluded from the analysis 
of efficacy because of protocol violations. Of the 
remaining 15 patients, two patients receiving 
vigabatrin 3 g/day became seizure-free for the 
entire active treatment period, one continuing 
into the washout period. Of the other three 
patients receiving vigabatrin 3 g/day, three had 
seizure-free periods, two during the first treat- 
ment period and one during the second period 
extending into the washout phase. None of the 
eight patients receiving vigabatrin 2 g/day was 
seizure-free during the entire active period, but 
four were seizure-free during their second period 
and four during the first part of the active period. 
To summarize, two patients were seizure-free for 
the entire active treatment periods, 11 had 
seizure-free periods during the study, and two 
showed a placebo-response during the second 
four-week treatment period. 
The reduction in seizure frequency during 
vigabatrin treatment did not appear to be dose 
related. As shown in Table 2, relative to placebo, 
a 36% reduction in the mean back-transformed 
seizure rate was observed for patients receiving 
vigabatrin 2 g/day compared with a 31% mean 
reduction for patients treated with vigabatrin 
3 g/day. 
The number of seizure-free days and longest 
seizure-free period were significantly (P < 0.01) 
longer during vigabatrin therapy compared with 
placebo. The median number of seizure-free days 
increased from a mean of 19 days during placebo 
treatment, to 22 during vigabatrin therapy; the 
longest seizure-free period rose from six days 
during placebo therapy to 10.5 days during 
vigabatrin therapy (Fig. 2). 
Seizure severity and duration 
Analysis of the reduction in seizure rate during 
vigabatrin therapy found a decrease in the mean 
seizure rate at all centres, ranging from a 22-62% 
overall reduction in seizures. This variation was 
probably due to the small number of patients 
recruited at some centres, and highlights the 
heterogeneity of this patient population. 
Forty-two per cent of patients reported a 
reduction of seizure severity during vigabatrin 
therapy compared with 20% of those receiving 
placebo. During vigabatrin therapy, 36% of 
patients reported a decrease in the duration of 
length of individual seizures compared with 20% 
during the placebo treatment phases. Thirty-two 
per cent of patients treated with vigabatrin 
reported a trend towards less severe, shorter 
seizures during the period of active treatment; by 
Table 1: Change in mean monthly seizure rate during double-blind therapy 
Treatment n Median Mean square 
period seizure root 
frequency 
(rate per 
month) 
Mean back- 
transformed 
seizure rate 
Reduction in 
mean back 
transformed 
seizure rate (%) 
Placebo 80 15.4 4.59 21.06 -34% 
Vieabatrin 80 9.4 3.72 13.83 
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Table 2: Changes in mean monthly seizure rate during double-blind therapy according to dose of vigabatrin 
Treatment n Median Mean square Mean back- Reduction in 
period seizure root transformed mean back 
frequency seizure rate transformed 
(rate per seizure rate (%) 
month) 
Vigabatrin 
2 g/day 
Placebo 
Vigabatrin 
3 g/day 
Placebo 
42 11.5 3.13 14.1 -36%* 
42 15.8 4.69 21.9 
38 8.6 3.71 13.8 -31%: 
38 11.2 4.48 20.1 
*No statistically significant difference between doses. 
comparison, 16% of patients reported this 
combination of seizure improvement during the 
placebo treatment phase (P = 0.06). In the 
second month of active treatment, more than 
one-third of patients (38%, n = 31) had a 
combination of both milder and shorter duration 
seizures compared with 7.5% (n = 14) on placebo 
(P < 0.01). 
Global evaluation of well-being 
A global evaluation of well-being was made by 
both the investigator and the patient after two 
months’ treatment. The well-being of 23% of 
patients (n = 18) taking vigabatrin was assessed 
by the investigator as ‘very good’ or ‘good’ 
compared with 9% (n = 7) on placebo (P < 
0.001). This concurred with patients’ assessment 
of their own well-being. That is, 30% patients 
(n = 24) rated their well-being as ‘very good’ or 
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Seizure-free days Seizure-free periods 
Fig. 2: Comparison of seizure-free days and the longest 
seizure-free period. Statistically significant (P < 0.01) 
differences between treatment groups for both parameters. 
0, Placebo; n , vigabatrin. 
‘good’ compared with 13% (n = 10) on placebo 
(P c 0.01). 
Tolerability 
Two patients discontinued therapy because of 
adverse events; following three weeks of vigaba- 
trin 2 g/day, one patient experienced depression 
that may have been drug-related. Another patient 
who had received placebo reported severe 
fatigue, visual impairment, nausea and vomiting 
throughout the first study period and subsequent 
washout phase. 
Adverse events were reported throughout the 
study. One or more adverse events were reported 
by five patients during the baseline phase, by 36 
receiving vigabatrin 2 g/day, by 27 receiving 
vigabatrin 3 g/day, by 26 receiving placebo 
(2 g/day), and 21 receiving placebo (3 g/day). 
The most commonly reported adverse events are 
reported in Table 3. Adverse events were 
primarily of central nervous system origin. 
Dose-related increases in the incidence of adverse 
events occurred only for drowsiness and visual 
adverse events (diplopia, ataxia, visual abnor- 
mality): however, the small numbers of patients 
experiencing these events precludes a firm con- 
clusion regarding the trends observed in this 
study. Depression was the only behavioural 
change reported consistently during vigabatrin 
treatment; aggressive reactions were reported by 
three patients (7.3%) receiving placebo (3 g/day) 
but were not reported in the vigabatrin treatment 
groups. Furthermore, no patient reported psy- 
chosis during this study. 
No clinically significant changes were noted for 
any haematology or biochemistry test result and 
no significant drug interactions, as determined by 
the investigators, were observed during the study. 
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Table 3: Comparative incidence of most commonly 
reported adverse events 
Incidence of adverse events most frequently reported by dose 
(%) 
Vigabatrin Vigabatrin Placebo Placebo 
2 g/day 3 g/day 2 g/day 3 g/day 
(n = 49)* (n = 43) (n = 49) (n = 41) 
Drowsiness 
Fatigue 
Weight 
increase 
Convulsions 
Headache 
Depression 
Agitation 
Tremor 
Diplopia 
Dizziness 
Ataxia 
Visual 
abnormality 
14.3 20.9 
14.3 11.6 
12.2 9.3 
12.2 2.3 2.0 0 
10.2 4.1 8.2 4.9 
a.2 9.0 2.0 0 
8.2 2.3 6.1 2.4 
8.2 0 2.0 2.4 
6.1 11.6 0 4.9 
6.1 9.3 2 7.3 
4.1 7.0 0 2.4 
2.0 7.0 2.0 4.9 
’ 8.2 12.2 
10.2 4.9 
2.0 7.3 
*Patient numbers reflect all patients enrolled in a study 
group. 
DISCUSSION 
The results of this study indicate that vigabatrin, 
when added to conventional therapy as a daily 
dose of either 2 or 3 g, is significantly more 
effective than placebo in reducing the frequency 
of seizures in patients suffering from uncontrolled 
partial seizures. Compared with placebo, vigabat- 
rin reduced the seizure rate by 34%; 42% (34/80) 
of the patients had a 50% or greater reduction of 
seizure frequency during active treatment as 
compared with placebo. These response rates 
compare favourably with those reported in recent 
studies of vigabatrin’@12. 
In a single-blind, placebo-controlled studyi of 
101 patients with epilepsy (most with partial 
seizures), patients had vigabatrin 2 g/day added 
to current therapy for eight weeks; they could 
then be titrated to a maximum dose of 4 g/day 
over 16 weeks. The median number of seizures 
per month decreased from 16 during the placebo 
phase to five during the last eight weeks of 
vigabatrin therapy (a reduction of 69%; P < 
0.0001). A reduction in seizure frequency of 
greater than 50% compared with placebo was 
observed in 60 (59%) of patients. 
An assessment of 54 patients with drug- 
resistant partial epilepsy who had vigabatrin 
added to their regimen found a decrease in 
median monthly seizure frequency from 12.5 
episodes at baseline to 3.3 episodes after three 
months of therapy, and the rate was 3.9 episodes 
after five years of treatment”. Fifty-four per cent 
of patients treated under the long-term phase of 
that study had a 50% or greater decrease in 
seizure frequency at five years compared with 
baseline’ ’ . 
A recent long-term study found that vigabatrin 
effectively reduced the seizure rate in patients 
with partial seizures following 52-78 months of 
treatment”. In this study, median monthly 
seizure frequency during the last two months of 
vigabatrin therapy was 3.5 episodes compared 
with 10 episodes during the initial placebo phase 
(P c 0.01). 
Earlier studies found that while a daily dose of 
1.5 g effectively reduced seizure activity com- 
pared with placeboh.‘, this dose was less effective 
than 3 g/day. In this study, the reductions in 
seizure rate of 36% and 31% for the 2 g and 3 g 
doses, respectively, suggest that no clinically 
relevant differences in response rate was ob- 
served between these doses compared with 
placebo. Two patients receiving the 3 g/day dose 
became seizure-free for the entire active treat- 
ment period, a seizure-free period was reported 
for 19% (8/42) patients receiving 2 g/day and for 
13% (5/38) receiving 3 g/day. Although these 
trends are important, it should be recognized that 
the interpatient variability in studies of AEDs can 
confound the interpretation of some results. In 
this case, two patients reported seizure-free 
periods related to placebo treatment, one during 
the washout phase after placebo treatment and 
the other for the entire placebo period. In some 
cases, patients were seizure-free during the 
washout period following active treatment. These 
data highlight the need to consider the in- 
dividuality of patient responses and the com- 
plexity of analysing responses to therapy. 
Twice as many patients (n = 26) reported a 
combination of less severe and shorter duration 
seizures during vigabatrin treatment (32%) com- 
pared with those receiving placebo treatment 
(n = 13, 16%). Patient anxiety about epilepsy has 
been related to the length of the seizure-free 
period; a longer period is associated with an 
improvement in patient well-being”. In our 
study, the length of the seizure free-period 
increased from 19 days during placebo treatment 
to 22 days during vigabatrin therapy. Although 
not statistically significant, these data indicate 
that the drug could contribute to a reduction in 
anxiety about seizure recurrence. 
The incidence of adverse events during vigaba- 
trin therapy was low and overall did not rise with 
increasing vigabatrin dose. Only drowsiness and 
visual abnormalities increased with vigabatrin 
dose. The only event assessed as a behavioural 
change consequent to vigabatrin therapy was 
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depression, which occurred in approximately 7% 
of vigabatrin-treated patients and about 1% of 
placebo-treated patients. However, symptoms of 
depression are known to occur more often in 
patients who suffer from epilepsy than in the 
normal population. Aggressive reactions were not 
reported during vigabatrin therapy but were 
noted in patients receiving placebo, thereby 
demonstrating the extent of confounding factors 
associated with psychological assessments in this 
type of study. None of the patients in this 
short-term study reported psychosis. 
Good seizure control and a low incidence of 
disturbing side-effects, together with a reduction 
in falls and trauma secondary to tonic and atonic 
seizures, contribute to an increase in the quality 
of life of epileptic patients’. The improvement in 
seizure control, together with a low incidence of 
adverse events, observed in this study suggest that 
vigabatrin therapy may play a role in improving 
the quality of life of patients with partial seizures. 
In conclusion, the results of this study provide 
additional evidence for the efficacy of vigabatrin 
in treating patients with localized and related 
epilepsy, and also indicates that 2 g/day of 
vigabatrin is as effective as 3 g/day as add-on 
therapy for patients suffering from previously 
uncontrolled partial seizures. The tolerability 
profiles of these two doses were similar. 
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